Pharvaris (NASDAQ:PHVS) Insider Sells $55,967.40 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 1,829 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.60, for a total value of $55,967.40. Following the completion of the transaction, the insider directly owned 48,945 shares of the company’s stock, valued at approximately $1,497,717. This trade represents a 3.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total value of $169,100.74.

Pharvaris Stock Up 1.3%

PHVS stock opened at $29.86 on Friday. The company has a market cap of $1.95 billion, a PE ratio of -9.39 and a beta of -2.34. The business has a 50-day simple moving average of $28.72 and a 200 day simple moving average of $27.07. Pharvaris N.V. has a 52 week low of $15.51 and a 52 week high of $33.33.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, analysts anticipate that Pharvaris N.V. will post -3.25 EPS for the current fiscal year.

Institutional Trading of Pharvaris

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL bought a new stake in shares of Pharvaris in the 3rd quarter valued at about $1,943,000. Patient Square Capital LP grew its position in shares of Pharvaris by 41.4% in the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock valued at $8,617,000 after buying an additional 101,098 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 710.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after buying an additional 23,743 shares during the last quarter. Integral Health Asset Management LLC bought a new stake in shares of Pharvaris in the 3rd quarter valued at about $4,990,000. Finally, Boothbay Fund Management LLC grew its position in shares of Pharvaris by 735.1% in the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock valued at $3,373,000 after buying an additional 118,994 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Royal Bank Of Canada lowered their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, UBS Group set a $74.00 price target on Pharvaris in a report on Wednesday, May 13th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.